润本生物技术股份有限公司 第一章 总则 第一条 为加强润本生物技术股份有限公司（以下简称"本公司"）分、子公 司的管理，规范分、子公司的经营管理行为，维护公司利益和投资者利益，根据 《中华人民共和国公司法》 （以下简称《公司法》）、 《中华人民共和国证券法》 （以 下简称《证券法》）、《企业内部控制基本规范》《上海证券交易所股票上市规则》 等法律、法规、规范性文件以及《润本生物技术股份有限公司章程》（以下简称 《公司章程》）的有关规定，制定本制度。 第二条 本制度所称子公司指公司直接或间接持有其 50%以上股份，或者持 有其股份不足 50%但能够决定其董事会半数以上成员的组成，或者通过协议或其 他安排等方式实际控制的公司。 第三条 子公司具有法人资格，依法独立承担民事责任。 第四条 公司依法对子公司享有资产受益、重大决策、选择管理者等股东权 利。 《中华人民共和国证券法》 等相关法律、法规及规范性文件的规定，建立健全法人治理结构和内部管理制度。 第九条 子公司日常生产经营活动的计划、组织、经营活动的管理、对外投 资项目的确定等经济活动，应满足公司生产经营决策总目标、长期规划和发展的 要求以及符合与上市相关法律 ...

Core Viewpoint - The company has established regulations to ensure the proper conduct of its controlling shareholders and actual controllers, aiming to protect the rights of all shareholders, especially minority shareholders [1][2]. Group 1: Responsibilities of Controlling Shareholders and Actual Controllers - Controlling shareholders and actual controllers must comply with relevant laws and regulations, promote the company's standardized operations, and enhance overall company quality [2]. - They are required to act in good faith, fulfill shareholder obligations, and seek the common development of the company and all shareholders [2]. - They must maintain the company's independence and not abuse their control to seek illegal benefits or harm the rights of the company and other shareholders [2][3]. Group 2: Governance and Decision-Making - Controlling shareholders and actual controllers should establish systems to clarify decision-making processes for significant company matters and ensure the company's independence [3]. - They must support the independent operation of the company's board of directors and other institutions, avoiding interference in personnel decisions and operational independence [4][14]. Group 3: Financial Independence - Controlling shareholders and actual controllers must maintain the company's financial independence, avoiding any non-operational occupation of company funds and ensuring separate financial accounting systems [4][12]. - They are prohibited from using company funds for personal expenses or requiring the company to provide guarantees unlawfully [5][6]. Group 4: Information Disclosure - Controlling shareholders and actual controllers must fulfill information disclosure obligations, ensuring that disclosed information is timely, fair, truthful, accurate, and complete [19][20]. - They are required to notify the company of any significant changes in their shareholding or control status and cooperate with the company's information disclosure processes [9][10]. Group 5: Share Transfer and Control Stability - Controlling shareholders and actual controllers must maintain control stability and ensure that any transfer of control is fair and does not harm the company or other shareholders' rights [27][28]. - They must conduct due diligence on potential transferees before transferring control and ensure compliance with all obligations before such transfers [13][14].

Group 1 - The company aims to strengthen and standardize its internal audit work to protect shareholders' rights and improve audit quality [1][2] - Internal audit is defined as an evaluation activity conducted by internal personnel to assess the effectiveness of internal controls and risk management, as well as the authenticity and completeness of financial information [1][2] - The board of directors is responsible for establishing and implementing the internal control system, ensuring the accuracy and completeness of related disclosures [2][3] Group 2 - The audit committee, composed of at least three directors with a majority being independent directors, oversees the internal audit department and ensures its independence from the finance department [2][3][6] - The internal audit department is tasked with evaluating the integrity and effectiveness of internal controls across the company and its subsidiaries [3][12] - The audit committee is responsible for reviewing the annual internal audit plan and reporting on the progress and quality of the internal audit work [3][4] Group 3 - The internal audit department must conduct checks on high-risk investments and significant transactions, reporting any violations or irregularities to the audit committee [4][11] - The internal audit department is required to assess the internal control systems related to financial reporting and information disclosure, focusing on areas such as large non-operating fund transactions and related party transactions [8][10] - The company must disclose any significant internal control deficiencies or risks identified during audits to the Shanghai Stock Exchange [13][15] Group 4 - The internal audit department is mandated to conduct audits on the use of raised funds, ensuring compliance with established plans and regulations [11][12] - The company is required to maintain a robust internal control system, with performance evaluations linked to the effectiveness of these controls [16][40] - The internal audit department must establish a system for audit documentation and maintain records for at least five years [13][36]

润本生物技术股份有限公司 第一章 总 则 第一条 为规范润本生物技术股份有限公司（以下简称"公司"）的组织和行为， （以下简称"《公司法》"）、 保证股东会依法行使职权，根据《中华人民共和国公司法》 《中华人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公 司自律监管指引第1号——规范运作》等有关法律、行政法规、部门规章和规范性 文件（以下合称"法律法规"）以及《润本生物技术股份有限公司章程》 （以下简称"《公 司章程》"）规定，特制定本议事规则。 第二条 公司召开股东会时适用本规则。 第三条 本规则对与会股东、公司全体董事、高级管理人员、股东会的有关工 作人员、列席股东会的其他人员具有约束力。 第四条 公司董事会应严格遵守《公司法》及其他法律法规、《公司章程》关于召 开股东会的各项规定，认真、按时组织好股东会。公司全体董事对股东会的正常召开负有 诚信勤勉的责任，不得阻碍股东会依法履行职权。 第二章 股东会的职权 第五条 股东会是公司的最高权力机构，依法行使以下列职权： （一）选举和更换董事，决定有关董事的报酬事项； （六）对公司合并、分立、解散、清算或者变更公司形式等事项作出决议； （七） ...

润本生物技术股份有限公司 第一章 总则 第一条 为进一步完善润本生物技术股份有限公司（以下简称"公司"）的法 人治理结构，规范公司董事的选举，切实保证所有股东充分行使选择董事的权利， 维护中小股东利益，根据《中华人民共和国公司法》（以下简称《公司法》）、 第二章 董事候选人的提名 第七条 公司董事会、单独或者合并持有公司股份1%以上的股东可以以提案 的方式书面提出董事候选人。 第八条 被提名的董事候选人应符合《公司法》《上市公司治理准则》《公 司章程》等法律、法规及公司内部规章要求。被提名的独立董事候选人还应符合 《上市公司独立董事管理办法》等规定的任职条件。 提名人应当充分了解被提名人职业、学历、职称、详细的工作经历、全部兼 职情况。对于独立董事候选人，提名人还应当对其担任独立董事的资格和独立性 发表意见。公司应在股东会召开前披露董事候选人的详细资料，保证股东在投票 时对候选人有足够的了解。 《上市公司治理准则》、《上市公司独立董事管理办法》等规范性文件及《润本 生物技术股份有限公司章程》（以下简称《公司章程》）等有关规定，制定本细 则。 第二条 本细则所称累积投票制，是指公司股东会选举董事时，每一股份拥 ...

润本生物技术股份有限公司 第一章 总则 第一条 为了规范润本生物技术股份有限公司（以下简称"公司"）的对外 投资行为，降低对外投资的风险，提高投资效益，合理、有效地使用资金，根据 《中华人民共和国公司法》 《中华人民共和国证券法》 《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等国家法 律、法规、规范性文件和《润本生物技术股份有限公司章程》（以下简称"《公 司章程》"）的规定，特制定本制度。 第二条 公司对外投资管理的基本原则：符合公司发展战略和发展思路，合 理配置企业资源，促进要素优化组合，有利于培育公司核心竞争力，创造良好经 济效益。 第三条 本制度适用于公司及各级子公司，子公司包括全资子公司和控股子 公司，以及虽然持股数未超过 50%，但可以对其实施控制的公司。 第二章 对外投资范围及权限 第四条 本制度所指的对外投资是指：公司为获取未来收益将一定数量的货 币资金、股权以及经评估后的实物或无形资产作价出资，进行各种形式的投资活 动的行为。包括但不限于： （一）单独或与他人共同出资设立公司、合营企业、联营企业等经济实体； （二）收购、出售、置换其他公司股权； ...

Group 1: Recent IPO Activity - Eight companies went public in the US last week, including two SPACs, with seven IPOs and eight SPACs filing initial applications [1][4] - Bullish, a cryptocurrency exchange, raised $1.1 billion at a valuation of $5.8 billion, with a first-day return of 84% and a closing increase of 88% [1][4] - Miami International Holdings raised $345 million at a valuation of $2.3 billion, with a first-day return of 34% and a closing increase of 35% [1][4] Group 2: Performance of Other IPOs - NusaTrip, an Indonesian online travel agency, raised $15 million at a valuation of $75 million, closing down 2% [2][4] - Nasus Pharma, an Israeli biotech company, raised $10 million at a valuation of $74 million, closing up 1% [2][4] - Magnitude International, a Singapore-based electrical installation company, raised $9 million at a valuation of $140 million, closing down 63% [2][4] Group 3: Upcoming IPOs and Market Outlook - No IPOs are scheduled for the current week, but some smaller issuers may still price [7] - Major issuers like Gemini and Via Transportation have joined the IPO pipeline, with expectations for larger listings after Labor Day [7]

Core Viewpoint - MIRXES-B, a Singapore-based microRNA technology company, has seen its stock price rise significantly since its IPO, reflecting strong market interest and potential growth opportunities in the molecular diagnostics sector [1] Company Summary - MIRXES-B's stock price reached a new high of 47.8 HKD, marking an 8.1% increase during trading, with a market capitalization of approximately 13.2 billion HKD [1] - Since its listing on May 23, the stock has appreciated by 105% from its initial offering price of 23.3 HKD [1] Industry Summary - The company has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO, a company listed on the Indonesian stock exchange, to collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of cancers with high incidence and mortality rates in Indonesia [1] - The memorandum is set for a duration of 12 months, indicating a strategic move to expand into emerging markets with high growth potential [1]

Core Viewpoint - The stock of Pagoda Biopharma-B (02565) has surged over 15%, reaching a new high of 37 HKD, driven by the approval of Novo Nordisk's semaglutide for a new indication, which has heightened interest in the GLP-1 sector [1] Company Summary - Pagoda Biopharma is a biotechnology company focused on the independent research and development of innovative therapies for chronic diseases, with six drugs in the pipeline, four of which are related to GLP-1 drugs targeting obesity, overweight, and diabetes [1] - The most promising product for commercialization is PB-119, a GLP-1 receptor agonist aimed at weight loss [1] Industry Summary - China is the second-largest pharmaceutical market globally and has the largest population of diabetes (projected to reach 164 million by 2030) and overweight individuals (estimated to be between 200 million to 250 million by 2030), making it a strategic battleground for global pharmaceutical giants and local companies [1] - With the continuous release of market potential, Pagoda Biopharma is expected to reshape the domestic T2DM treatment market landscape through its differentiated innovation capabilities and core product, Vepaglutide [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Pag BioPharma-B (02565), which increased over 15% to reach a new high of 37 HKD, driven by the approval of Novo Nordisk's semaglutide for a new indication in the MASH category, boosting interest in the GLP-1 sector [1] - Pag BioPharma is focused on the research and development of innovative therapies for chronic diseases, with six drugs in the pipeline, four of which are related to GLP-1 drugs targeting obesity, overweight, and diabetes [1] - The most promising product for commercialization is PB-119, a GLP-1 receptor agonist aimed at weight loss [1] Group 2 - The Chinese pharmaceutical market is the second largest globally and has the highest number of diabetes patients, projected to reach 164 million by 2030, and an overweight population estimated between 200 to 250 million by 2030, making it a strategic battleground for global pharmaceutical giants and local companies [1] - With the continuous release of market potential, Pag BioPharma is expected to reshape the domestic T2DM treatment market landscape through its differentiated innovation capabilities and core product, Weipin peptide, which possesses BIC attributes [1] - The article suggests that the intrinsic value of Pag BioPharma is likely to accelerate as it capitalizes on the growing interest in the GLP-1 sector [1]